JP7724866B2 - 抗体薬物複合体およびその用途 - Google Patents

抗体薬物複合体およびその用途

Info

Publication number
JP7724866B2
JP7724866B2 JP2023547736A JP2023547736A JP7724866B2 JP 7724866 B2 JP7724866 B2 JP 7724866B2 JP 2023547736 A JP2023547736 A JP 2023547736A JP 2023547736 A JP2023547736 A JP 2023547736A JP 7724866 B2 JP7724866 B2 JP 7724866B2
Authority
JP
Japan
Prior art keywords
seq
antibody
claudin
variable region
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023547736A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022078523A5 (https=
JP2024530368A (ja
JP2024530368A5 (https=
Inventor
朝 紅 胡
虎 李
博 陳
剛 徐
瑩 王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Miracogen Inc
Keymed Biosciences Chengdu Co Ltd
Original Assignee
Shanghai Miracogen Inc
Keymed Biosciences Chengdu Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Miracogen Inc, Keymed Biosciences Chengdu Co Ltd filed Critical Shanghai Miracogen Inc
Publication of JP2024530368A publication Critical patent/JP2024530368A/ja
Publication of JPWO2022078523A5 publication Critical patent/JPWO2022078523A5/ja
Publication of JP2024530368A5 publication Critical patent/JP2024530368A5/ja
Priority to JP2025130431A priority Critical patent/JP2025183203A/ja
Application granted granted Critical
Publication of JP7724866B2 publication Critical patent/JP7724866B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023547736A 2020-10-15 2021-10-19 抗体薬物複合体およびその用途 Active JP7724866B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025130431A JP2025183203A (ja) 2020-10-15 2025-08-05 抗体薬物複合体およびその用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011105383.0A CN114366818B (zh) 2020-10-15 2020-10-15 抗体药物偶联物及其应用
PCT/CN2021/124698 WO2022078523A1 (zh) 2020-10-15 2021-10-19 抗体药物偶联物及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025130431A Division JP2025183203A (ja) 2020-10-15 2025-08-05 抗体薬物複合体およびその用途

Publications (4)

Publication Number Publication Date
JP2024530368A JP2024530368A (ja) 2024-08-20
JPWO2022078523A5 JPWO2022078523A5 (https=) 2024-09-25
JP2024530368A5 JP2024530368A5 (https=) 2024-09-25
JP7724866B2 true JP7724866B2 (ja) 2025-08-18

Family

ID=81138741

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023547736A Active JP7724866B2 (ja) 2020-10-15 2021-10-19 抗体薬物複合体およびその用途
JP2025130431A Pending JP2025183203A (ja) 2020-10-15 2025-08-05 抗体薬物複合体およびその用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025130431A Pending JP2025183203A (ja) 2020-10-15 2025-08-05 抗体薬物複合体およびその用途

Country Status (14)

Country Link
US (2) US20230381336A1 (https=)
EP (1) EP4230225A4 (https=)
JP (2) JP7724866B2 (https=)
KR (1) KR102921110B1 (https=)
CN (1) CN114366818B (https=)
AU (1) AU2021359562A1 (https=)
CA (1) CA3198667A1 (https=)
CL (1) CL2023001073A1 (https=)
CO (1) CO2023005979A2 (https=)
CR (1) CR20230207A (https=)
IL (1) IL302122A (https=)
MX (1) MX2023004236A (https=)
WO (1) WO2022078523A1 (https=)
ZA (1) ZA202304381B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260042860A1 (en) * 2022-08-04 2026-02-12 Memorial Sloan-Kettering Cancer Center Anti-cd24 antibodies and uses thereof
EP4591886A1 (en) * 2022-09-19 2025-07-30 Shanghai Miracogen Inc Treatment of nasopharyngeal carcinoma by using antibody conjugate targeting egfr
CN119894536A (zh) * 2022-09-22 2025-04-25 乐普生物科技股份有限公司 Gpc3抗体药物偶联物及其应用
WO2025078686A1 (en) 2023-10-12 2025-04-17 Sotio Biotech A.S. Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer
WO2025088105A1 (en) 2023-10-27 2025-05-01 Keymed Biosciences (Chengdu) Co., Ltd Cancer treatment with anti-claudin 18.2 adc
WO2025086268A1 (en) 2023-10-27 2025-05-01 Keymed Biosciences (Chengdu) Co., Ltd. Cancer treatment with anti-claudin 18.2 adc
WO2025086270A1 (en) 2023-10-27 2025-05-01 Keymed Biosciences (Chengdu) Co., Ltd. Cancer treatment with anti-claudin 18.2 adc

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018513146A (ja) 2015-04-15 2018-05-24 ガニメド ファーマシューティカルズ ゲーエムベーハー クローディン１８．２に対する抗体を含む薬物コンジュゲート
JP2020510677A (ja) 2016-11-25 2020-04-09 マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド 抗体−薬物複合体化のための二置換マレインアミドリンカーならびにその調製方法および使用
WO2020211792A1 (zh) 2019-04-19 2020-10-22 康诺亚生物医药科技（成都）有限公司 肿瘤治疗剂及其应用
JP2021527441A (ja) 2018-06-17 2021-10-14 エルアンドエル バイオファーマ カンパニー リミテッド Ｃｌｄｎ１８．２を標的とする抗体、二重特異性抗体、ａｄｃ及びｃａｒならびにその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109810039B (zh) * 2017-11-22 2021-11-12 迈威(上海)生物科技股份有限公司 一种用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途
CN111110862A (zh) * 2018-11-01 2020-05-08 上海健信生物医药科技有限公司 抗cldn18．2抗体的药物偶联体及其制备方法和用途
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018513146A (ja) 2015-04-15 2018-05-24 ガニメド ファーマシューティカルズ ゲーエムベーハー クローディン１８．２に対する抗体を含む薬物コンジュゲート
JP2020510677A (ja) 2016-11-25 2020-04-09 マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド 抗体−薬物複合体化のための二置換マレインアミドリンカーならびにその調製方法および使用
JP2021527441A (ja) 2018-06-17 2021-10-14 エルアンドエル バイオファーマ カンパニー リミテッド Ｃｌｄｎ１８．２を標的とする抗体、二重特異性抗体、ａｄｃ及びｃａｒならびにその使用
WO2020211792A1 (zh) 2019-04-19 2020-10-22 康诺亚生物医药科技（成都）有限公司 肿瘤治疗剂及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Manar HAMMOOD et al.，"Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs) - A Necessity for Future ADC Researchand Development"，Pharmaceuticals，2021年07月15日，Vol. 14, No. 674，p.1-33，DOI: 10.3390/ph14070674
Puregmaa KHONGORZUL et al.，"Antibody-Drug Conjugates: A Comprehensive Review"，MolecularCancer Research，2020年01月01日，Vol. 18, No. 1，p.3-19，DOI: 10.1158/1541-7786.MCR-19-0582
ZHU Guoyun, et al.，"Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADCModalities for the Treatments of Gastric and Pancreatic Cancer"，Scientific Reports，2019年11月08日，Vol. 9, No. 1，DOI: 10.1038/s41598-019-53130-4

Also Published As

Publication number Publication date
CL2023001073A1 (es) 2023-12-01
US20250032633A1 (en) 2025-01-30
KR20240074700A (ko) 2024-05-28
ZA202304381B (en) 2025-07-30
KR102921110B1 (ko) 2026-02-06
CR20230207A (es) 2023-10-26
WO2022078523A1 (zh) 2022-04-21
MX2023004236A (es) 2023-08-18
JP2024530368A (ja) 2024-08-20
EP4230225A1 (en) 2023-08-23
CO2023005979A2 (es) 2023-05-29
CN114366818B (zh) 2025-02-25
JP2025183203A (ja) 2025-12-16
AU2021359562A1 (en) 2023-05-25
CA3198667A1 (en) 2022-04-21
CN114366818A (zh) 2022-04-19
IL302122A (en) 2023-06-01
US20230381336A1 (en) 2023-11-30
EP4230225A4 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
JP7724866B2 (ja) 抗体薬物複合体およびその用途
JP7705809B2 (ja) 抗体薬物複合体の用量
CN109963591B (zh) B7h3抗体-药物偶联物及其医药用途
TWI712423B (zh) 抗ｔｒｏｐ２抗體-藥物結合物之製造方法
US11584801B2 (en) Anti-5T4 antibodies and antibody-drug conjugates
TWI487712B (zh) 多重特異性抗體
CN101939336B (zh) Axl抗体
CN102421802B (zh) 人源化的axl抗体
EP2918603B1 (en) Antibody capable of specifically recognizing transferrin receptor
TW201138816A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
JP7305549B2 (ja) ヒト化抗ｔｐｂｇ抗体およびその製造方法、その複合体および使用
CN112390885A (zh) 一种trop2抗体及其制备方法、其偶联物和应用
JP2023506805A (ja) 抗ｃｅａ抗体－エキサテカン類似体複合体及びその医薬用途
US20230322943A1 (en) Antibody binding to human cd38, preparation method thereof, and use thereof
HK40090672A (en) Antibody-drug conjugate and application thereof
EA051410B1 (ru) Конъюгат антитело-лекарственное средство и его применение
TW202602936A (zh) 抗FGFR2b抗體藥物偶聯物及其應用
EP4219553A1 (en) Anti-tigit antibody and double antibody and their application
JP2025531401A (ja) Ｇｐｃ３抗体薬物複合体及びその使用
CA3252302A1 (en) Combination of antibody-drug conjugate and anti-sirp.alpha. antibody
HK40089099A (en) Anti-tigit antibody and double antibody and their application
HK40002989B (en) Method for producing an anti-trop2 antibody-drug conjugate
HK1147275B (en) Axl antibodies

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240712

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240902

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250805

R150 Certificate of patent or registration of utility model

Ref document number: 7724866

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117